The fine particle dose delivered via dry powder inhalers (DPIs) is often affected by the inspiratory flow rate generated during inhalation. This has clinical implications, since the fine particle dose determines the amount of drug reaching the lungs. With Easyhaler 1 DPI the fine particle dose remains relatively constant over the range of inspiratory flow rates from 30-60 l min 71 . The aim of this study was to confirm that clinical efficacy is maintained even at low flow rates by comparing the bronchodilating effect of salbutamol (100 mg) delivered via Easyhaler 1 at a target inspiratory flow of 30 l min 71 with the same dose of salbutamol via pressurised metered-dose inhaler (pMDI) plus spacer.
Introduction
Increasingly, dry powder inhalers (DPIs) are prescribed in preference to traditional aerosols -pressurized metereddose inhalers (pMDIs) -which are associated with a number of problems. These include sub-optimal use resulting from the failure of patients to properly coordinate inhaler actuation with inspiration (1) (2) (3) , and the unacceptable environmental effects of chlorofluorocarbons (4) . In addition, the propellants and lubricants in pMDIs can result in paradoxical, acute bronchoconstriction in some patients (5) (6) (7) (8) (9) .
While DPIs can overcome the drawbacks of pMDIs, it is essential that the potential therapeutic benefit of the device can be obtained at an achievable inspiratory flow rate, since inspiratory flow rate is known to affect the amount of drug deposited in the lungs (10) (11) (12) (13) (14) . As target inspiratory flow rate varies between different inhalers as a function of the resistance of the device, the objective of this study was to investigate the relationship between inspiratory flow rate and clinical efficacy for the new-generation DPI, Easyhaler 1 . Easyhaler 1 is a multidose DPI with 200 preloaded doses. The device has been designed to resemble a pMDI (Fig. 1) In an open study among asthmatic children with very low inspiratory flow rate, salbutamol inhaled via Easyhaler 1 was shown to produce equivalent bronchodilatation to salbutamol via pMDI (15) . Hence, the aim of this study was to confirm that the clinical efficacy of salbutamol is maintained at low flow rates through Easyhaler 1 . The bronchodilating effect of salbutamol (100 mg) via
Easyhaler
1 at a low flow rate (30 l min 71 ) was compared with the same dose of salbutamol via pMDI plus spacer.
Methods

SUBJECTS
Twenty-two paediatric and adult outpatients with diagnosed bronchial mild or moderate asthma were enrolled into the study (Table 1 ). The severity of asthma was graded according to the International Consensus Report on Diagnosis and Treatment of Asthma (16) . Twenty-one patients completed the study and one was excluded due to a protocol violation. The study included both male and female patients aged from seven to 65 years. None had smoked during the 6 months prior to the study. In the 4 weeks prior to the study, all patients had shown an improvement of at least 15% in forced expiratory volume in 1 sec (FEV 1 ) or peak expiratory flow (PEF) following inhalation of a sympathomimetic.
The study was conducted according to the principles of the current revision of the Declaration of Helsinki of the World Medical Assembly. The independent local Ethical Committee approved the study protocol. All patients received oral and written information about the study and gave their written informed consent to participation before entering into the study.
STUDY DESIGN
The study was conducted according to a randomized, double-blind with double-dummy technique, cross-over design with a single dose regimen and two treatment periods. The study was carried out at The Skin and Allergy Hospital, HUCH, Finland. The investigational drug was 100 mg salbutamol via Easyhaler 1 (Buventol Easyhaler 1 100 mg/dose, Orion Pharma, Finland). The comparative drug was 100 mg salbutamol via pMDI with a holding chamber (Ventolin 1 100 mg/dose with Volumatic 1 , Glaxo Wellcome, U.K.). Placebos of both devices were also used.
The study was carried out on two study days separated by an interval of at least 24 h. The study began at the same time on both study days. The patients were randomly divided into two groups to receive salbutamol via Easyhaler 1 and via pMDI plus spacer. On each study day, the patients inhaled first one dose from Easyhaler 1 and then a dose from the pMDI plus spacer, with either of the devices being placebo. The lung function tests were measured before inhalation and three times during a 1-h period thereafter.
The investigational drug was inhaled with a low peak inspiratory flow rate (PIFR) targeted at 30 l min 71 . Patients were taught the correct inhalation technique to achieve the target flow rate using an empty Easyhaler 1 in an air-tight chamber connected in series with a pneumotachograph (Spirotrack III, Vitalograph Ltd, U.K.). The drug dose from the pMDI plus spacer was inhaled within 1 sec following actuation with a low and deep inspiration according to the manufacturer's instructions.
Before the study measurements, patients abstained from controlled-release theophylline preparations for at least 48 h, from oral and inhaled long-acting sympathomimetics, sodium cromoglycate and nedocromil sodium for at least 12 h, and from inhaled short-acting sympathomimetics for at least 6 h. The use of oral, inhaled and topical corticosteroids, and the treatment of concomitant diseases, were unchanged during the study. The patients were not allowed to drink caffeine-containing drinks for 4 h before the lung function tests. had to be less than 15%. PIFR through Easyhaler 1 was measured on both study days. Adverse events (AEs) were recorded at the end of each study day as safety parameters.
METHODS
ANALYSIS
The null hypothesis in this study was that the two study drug-delivery device combinations had different bronchodilating effects. The alternative hypothesis assumed equivalence of the drug-device combinations. Both primary and secondary efficacy variables were used to collect evidence against the null hypothesis. The primary determinant of therapeutic efficacy was the maximum value of FEV 1 (FEV 1max ). Secondary variables included the area under the FEV 1 curve for the follow-up time, and FEV 1max as a percentage of the predicted value at baseline (during the first study day). FVC max and PEF max were treated as secondary variables.
A sample size of at least 17 patients was required to generate the statistical power necessary to detect a difference of 0?125 l in FEV 1 at the 5% significance level with 90% power. Analysis of the primary efficacy variable was performed using both Intention-To-Treat (ITT) and Per Protocol (PP) data sets. Other analyses were performed only for the ITT population. There were 17 patients in the PP data set and 21 in the ITT data set. An analysis of variance (ANOVA) model adapted for cross-over design was used for the statistical analysis of variables.
Results
PEAK INSPIRATORY FLOW RATE AND LUNG FUNCTION PARAMETERS
There was no significant difference in the primary efficacy variable between the PP and ITT data sets and, therefore, only results from ITT data set are presented. The mean (+SD) PIFR through Easyhaler 1 measured during the administration of active study treatment was 28?7 (+5?1) l min 71 . The mean (+SD) of FEV 1max after the inhalation of salbutamol from Easyhaler 1 was increased from 2?44 to 2?69 (+0?93) l, and after inhalation from pMDI plus spacer from 2?43 to 2?67 (+0?97) l ( Table 2 ). The estimated difference in FEV 1max between Easyhaler 1 and pMDI plus spacer was 0?01 l (90% confidence interval from 70?07 to 0?06 l). Both treatment groups showed a clinically significant (40?230 l) (17) improvement in FEV 1 within the first 15 min following inhalation of salbutamol. During the next 45 min there were no further significant changes (Fig. 2) . The mean AUC of FEV 1 during the follow-up time was almost equal after Easyhaler 1 and pMDI plus spacer, 10?2 and 10?1, respectively ( Table 2 ). The estimated difference in AUC of FEV 1 between Easyhaler 1 and pMDI plus spacer was 0?9 (90% confidence interval from 0?6 to 0?12).
FVC did not change significantly during the study (Table  3) . In both groups, the mean of the FVC max was close to the predicted and baseline values of FVC. The PEF results paralleled the FEV 1 data (Table 3) . No significant differences in primary or secondary efficacy variables were found between the treatments.
TOLERABILITY
All patients, including the one patient withdrawn after the first study day for protocol violation, were included in the safety analysis. No adverse events were reported during the study. Both treatments with salbutamol were considered safe and without any significant adverse drug reactions following a single 100 mg dose.
DISCUSSION
In this study, the bronchodilating effect of two different types of salbutamol inhaler was compared in paediatric and adult asthmatic patients. The pMDI plus large volume spacer was used optimally according to the manufacturer's instructions. However, for this study Easyhaler 1 DPI was used at a lower inspiratory flow rate (targeted 30 l min 71 ) than is normally recommended. Hence, the study is likely to reflect the real situation where a patient's ability to inhale is diminished, such as with a small child, or a person having an acute asthma attack. The lowest available dose of salbutamol via MDI and Easyhaler 1 , 100 mg, was used in the study trying to ensure that subjects are on a steep part of the dose-response curve instead of the plateau. However, there is a possibility that subjects would have achieved a maximal response.
There is considerable variability between DPIs in the effect of inspiratory flow rate on drug deposition and clinical efficacy. For example, with Turbuhaler 1 (Astra Draco, Sweden), which is one of the most widely used DPIs, the lung deposition of budesonide and terbutaline has been shown to decrease by half at low (28-36 l min 71 ) inspiratory flow compared to the optimal inspiratory flow rate of 60 l min 71 (10, 11) . Similarly, the clinical efficacy of formoterol dry powder inhaled from Aerolizer 1 DPI (ITALSEBER Farmaceutici Italy) is flow-dependent (12) . In contrast, the clinical efficacy of another widely used DPI, Diskus TM (Accuhaler TM ; Glaxo Wellcome, U.K.) has been reported to be almost flow-independent (18). Clickhaler 1 DPI (ML Laboratories PLC, U.K.) which is based on similar operating principles to Easyhaler 1 , has also been shown to be flow-independent in a study comparing the bronchodilating effect of 200 mg of salbutamol inhaled from Clickhaler 1 , and pMDI (19) . However, the high dose used (200 mg) diminishes the power of the result.
The fine particle dose from the Easyhaler 1 is only slightly influenced by the inspiratory flow rate in vitro (20 (15) . It should be noted that due to high internal resistance of the Easyhaler 1 greater inspiratory effort is required to achieve the same inspiratory flow rate through the Easyhaler 1 than needed for a gentle inhalation using a MDI and a spacer. However, a sub-optimal inspiratory flow rate of about 30 l min 71 through the Easyhaler 1 is achieved very easily (15) . The results of the present study with Easyhaler 1 are consistent with previous results showing equivalent clinical effect to a pMDI plus spacer (20, 22, 23) . The primary equivalence criterion, FEV 1max was clearly within predefined limits.
There was no correlation between age, or PIFR and the relative treatment effect of the two devices. In the present study, even a PIFR as low as 23 l min 71 through Easyhaler 1 is sufficient to obtain a similar treatment effect to normal inhalation from a pMDI plus spacer.
Conclusions
Even a reasonably low peak inspiratory flow rate (29 l min 71 ) through Easyhaler 1 produces an equivalent improvement in lung function to a correctly used pMDI plus spacer. Hence, Easyhaler 1 can be used with confidence in patients who may have difficulties in generating high levels of inspiratory flow rate, such as children and the elderly. 
